Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma

Capurro, Mariana; Wanless, Ian R.; Sherman, Morris; deBoer, Gerrit J.; Shi, Wen; Miyoshi, Eiji; Filmus, Jorge

doi:10.1016/s0016-5085(03)00689-9

Cited by 798 publications

(733 citation statements)

References 36 publications

Supporting

Mentioning

676

Contrasting

Unclassified

Order By: Relevance

“…For the development of APASL consensus statement for HCC, we performed additional systematic review of studies published from 2003 to August 2008. Summary of recent studies that met the inclusion criteria is shown in Table 1 [160][161][162][163][164][165][166][167][168][169]. The results of the studies that evaluated AFP, DCP, and AFP-L3 were grossly compatible with the previous review.…”

Section: Tumor Markerssupporting

confidence: 52%

“…However, the vast majority of reports were based on the immunohistochemical studies. Capurro et al [164] reported sensitivity of 0.53 and specificity of 0.95 with a cutoff value of 117 ng/mL on a study of serum samples from 53 healthy individuals and 71 patients with hepatitis or HCC. More evidence is needed to recommend GPC3 in daily practice.…”

Section: Glypican-3mentioning

confidence: 99%

See 1 more Smart Citation

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Introduction The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. Methods The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. 123Hepatol Int (2010) 4: 439-474 DOI 10.1007/s12072-010-9165-7 Results Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

show abstract

Section: Tumor Markerssupporting

confidence: 52%

Section: Glypican-3mentioning

confidence: 99%

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…GPC3 is a glycoprotein widely expressed on human hepatocellular carcinoma (HCC) cell, 27,28 and GPC3 has been developed as an antigen in CAR-T therapy for multiple pre-clinical and clinical application. 29,30 To further confirm the effect of DAP10 on second-generation CAR-T cells, we next constructed anti-GPC3 CAR vectors containing the DAP10 cytoplasmic domain at the 3ʹ end of the CAR (Figure 5A).…”

Section: Resultsmentioning

confidence: 99%

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

et al. 2018

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T cell immunotherapies have shown remarkable efficacy in treating multiple types of hematological malignancies but are not sufficiently effective at treating solid tumors. NKG2D is a strong activating receptor for NK cells and a co-stimulatory receptor for T cells. NKG2D signal transduction depends on DNAX-activating protein 10 (DAP10). Here, we introduced the cytoplasmic domain of DAP10 into the second-generation CARs M28z and G28z to generate M28z10 and G28z10, which target mesothelin (MSLN) and glypican 3 (GPC3), respectively. T cells expressing M28z10 or G28z10 showed enhanced and prolonged effector function against MSLN+ lung cancer or GPC3+ hepatocellular carcinoma cell lines in culture and secreted elevated levels of cytokines, including IL-2, IFN-γ, granzyme B, and GM-CSF. In addition, M28z10 CAR-T cells showed greater anti-tumor activity than those expressing M28z in both A549 cell line xenografts and human lung cancer patient-derived xenografts (PDX). Similarly, G28z10 exhibited higher efficacy in causing tumor regression than did G28z in hepatocellular carcinoma PDX. Therefore, our results show that DAP10 signaling contributes to the function of CAR-T cells in both lung cancer and hepatocellular carcinoma and can enhance the efficacy of CAR-T cells.

show abstract

“…In addition to the morphological criteria, some attempts have been made recently to utilize immunohistochemical markers for the diagnosis of well-differentiated HCCs [25][26][27][28][29][30][31]. Heat shock protein 70 (HSP70) [25,26], glypican 3 (GPC3) [25,[27][28][29], and glutamine synthetase (GS) [25,30,31] have been used independently or in combination.…”

Section: Total Process Of Biopsy Diagnosismentioning

confidence: 99%

Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application

Kondo

2008

Hepatol Int

View full text Add to dashboard Cite

Based on clinical and pathological experience, indistinct margin-type hepatocellular carcinomas (HCCs) were considered to be typical early-stage HCCs with good prognosis. For histological diagnosis, the assessment of stromal invasion (tumor invasion into portal tracts and fibrous septa) is very important. In differentiating stromal invasion from pseudoinvasion (benign hepatic tissue in the fibrous stroma), the following 5 items are useful: (1) macroscopic or panoramic views of the histological specimen, (2) amount of fibrous components of the stroma, (3) destruction of the structure of portal tracts, (4) loss of reticulin fibers around cancer cells, and (5) cytokeratin 7 immunostaining for ductular proliferation. Parenchymal features of early HCCs are summarized as follows: (1) thin trabecular structure, (2) hypercellularity, (3) hyperstainability of cytoplasm, and (4) microacinar formation. Detailed understanding of the total biopsy procedure and various difficult lesions is necessary for a correct biopsy diagnosis. Evaluation of noncancerous tissue is also required to attain a better understanding of the developmental process and clinical stages of HCCs.

show abstract

Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma

Cited by 798 publications

References 36 publications

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application

Contact Info

Product

Resources

About